 zidovudin interferon-alpha treatment patient aids-associ kaposi sarcoma effect addit interferon-alpha ifn-alpha patient aids-associ kaposi sarcoma non-random phase II clinic trial patient oral zidovudin mg ifn-alpha MU week evalu patient partial respons week month ifn-alpha dose escal patient respons myelotox mild fatigu dose-limit side-effect dose escal elig patient combin treatment decreas hiv-ag summari result addit ifn-alpha patient aids-associ kaposi sarcoma efficaci treatment